Skip to main content

Table 1 Protocols selected as the most common choice

From: Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey

  Protocol/trial (% of responding clinicians selecting protocol/trial as most common choice)
Adults with Ph − disease Adults with Ph + disease
France GRAALL 2014 50 ALL GRAALLPHAG06/EWALL-PH–01 35
Germany GMALL 08 2013 65 GMALL 08 2013 65
Italya GIMEMA LAL1913 42 GIMEMA LAL1811 25
Spain PETHEMA LAL-AR/2011 57 PETHEMA LAL PH–2008 59
UK UK ALL 14 70 UK ALL 14 68
  1. aUse of a range of GIMEMA protocols was reported for Italy, reflecting different populations (GIMEMA LAL1913, GIMEMA LAL1104, and GIMEMA LAL1308 for Ph − disease; GIMEMA LAL1811 and GIMEMA LAL1408 for Ph + disease)
  2. ALL, acute lymphoblastic leukemia; Ph, Philadelphia chromosome translocation